CoChat

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

Open access
Zobel, Emilie H, Wretlind, Asger, Ripa, Rasmus S, Rotbain Curovic, Viktor, von Scholten, Bernt J, Suvitaival, Tommi, Hansen, Tine W, Kjær, Andreas, Legido-Quigley, Cristina, Rossing, Peter · 2021 · BMJ Open Diabetes Research & Care

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Introduction: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can reduce risk of cardiovascular disease (CVD) in persons living with type 2 diabetes, however the mechanisms explaining this cardiovascular benefit are still debated. We investigated changes in the plasma lipidome following treatment with the GLP-1 RA liraglutide. Research design and methods: In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks. Fasting blood plasma was collected at baseline and at end-of-treatment. The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study. Treatment response of each lipid was tested with lipid-specific linear mixed-effect models comparing liraglutide with placebo. Bonferroni p<7.1e-03 was employed. The independence of the findings from clinical covariates was evaluated with adjustment for body mass index, HbA 1c, fasting status, lipid-lowering treatment and change in lipid-lowering treatment during the trial. Results: In total, 260 lipids were identified covering 11 lipid families. We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides. We confirmed these findings in adjusted models (p≤0.01). In the liraglutide-treated group, the individual lipids were reduced in the range of 14%–61% from baseline level, compared with 19% decrease to 27% increase from baseline level in the placebo group. Conclusions: Compared with placebo, liraglutide treatment led to a significant downregulation in ceramides, phospholipids and triglycerides, which all are linked to higher risk of CVD. These findings were independent of relevant clinical covariates. Our findings are hypothesis generating and shed light on the biological mechanisms underlying the cardiovascular benefits observed with GLP-1 RAs in outcome studies, and further strengthen the evidence base for recommending GLP-1 RAs to prevent CVD in type 2 diabetes. Trial registration number: NCT03449654.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2021-002395

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Lipidome-wide responses to liraglutide treatment compared with placebo. Lipid species grouped in panels according to lipid families (title of each panel). X-axis is the number of fatty-acid double bonds for the specific species (level of unsaturation) and Y-axis is the number of carbon atoms (total fatty acid chain length), and therefore each cell in the heat maps represents one lipid species (one individual lipid). Color indicates the coefficients from lipid-specific linear mixed-effect models. Blue colors represent lipids that are reduced in level by liraglutide treatment compared with placebo. Red colors represent lipids that are increased in level by liraglutide treatment compared with placebo. *p<0.05; **p<0.01. Cer, ceramides; DG, diglycerides; HexCer, hexocyl-ceramides; LacCer, lactosyl-ceramides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositoles; SM, sphingomyelins; TG, triglycerides.
Figure 1 Lipidome-wide responses to liraglutide treatment compared with placebo. Lipid species grouped in panels according to lipid families (title of each panel). X-axis is the number of fatty-acid double bonds for the specific species (level of unsaturation) and Y-axis is the number of carbon atoms (total fatty acid chain length), and therefore each cell in the heat maps represents one lipid species (one individual lipid). Color indicates the coefficients from lipid-specific linear mixed-effect models. Blue colors represent lipids that are reduced in level by liraglutide treatment compared with placebo. Red colors represent lipids that are increased in level by liraglutide treatment compared with placebo. *p<0.05; **p<0.01. Cer, ceramides; DG, diglycerides; HexCer, hexocyl-ceramides; LacCer, lactosyl-ceramides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositoles; SM, sphingomyelins; TG, triglycerides.CC BY-NC · PubMed Central
Figure 2 Percentage change after 26 weeks in average amount of individual lipids and in the traditional clinical lipid measurements following liraglutide and placebo treatment. Included are the 21 individual lipids significantly reduced by liraglutide compared with placebo and the traditional clinical lipid measurements, including HDL-cholesterol, LDL-cholesterol, triglycerides and total cholesterol. The traditional clinical lipid measurements were not significantly reduced by liraglutide compared with placebo treatment. Cer, ceramides; HDL, high-density lipoprotein; HexCer, hexocyl-ceramides; LDL, low-density lipoprotein; PC, phosphatidylcholines; PE, phosphatidylethanolamines; TG, triglycerides.
Figure 2 Percentage change after 26 weeks in average amount of individual lipids and in the traditional clinical lipid measurements following liraglutide and placebo treatment. Included are the 21 individual lipids significantly reduced by liraglutide compared with placebo and the traditional clinical lipid measurements, including HDL-cholesterol, LDL-cholesterol, triglycerides and total cholesterol. The traditional clinical lipid measurements were not significantly reduced by liraglutide compared with placebo treatment. Cer, ceramides; HDL, high-density lipoprotein; HexCer, hexocyl-ceramides; LDL, low-density lipoprotein; PC, phosphatidylcholines; PE, phosphatidylethanolamines; TG, triglycerides.CC BY-NC · PubMed Central
Figure 3 Baseline level of individual lipids for participants with versus without a history of cardiovascular disease. Shown are selected lipids that were significantly reduced by liraglutide compared with placebo treatment for participants with (n=23) vs without a history of cardiovascular disease (CVD). Levels are log10 transformed. Levels were generally higher for participants with a history of cardiovascular disease, although none of the differences were significant. A history of cardiovascular disease was defined as a history of acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, peripheral arterial thrombosis, claudication and/or nitroglycerin requiring angina pectoris. Cer, ceramides; PC, phosphatidylcholines; PE, phosphatidylethanolamines; TG, triglycerides.
Figure 3 Baseline level of individual lipids for participants with versus without a history of cardiovascular disease. Shown are selected lipids that were significantly reduced by liraglutide compared with placebo treatment for participants with (n=23) vs without a history of cardiovascular disease (CVD). Levels are log10 transformed. Levels were generally higher for participants with a history of cardiovascular disease, although none of the differences were significant. A history of cardiovascular disease was defined as a history of acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, peripheral arterial thrombosis, claudication and/or nitroglycerin requiring angina pectoris. Cer, ceramides; PC, phosphatidylcholines; PE, phosphatidylethanolamines; TG, triglycerides.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 38

Metadata

Authors
Zobel, E. H., Wretlind, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C., & Rossing, P.
Affiliations
  • Steno Diabetes Center Copenhagen (DK)
  • Rigshospitalet (DK)
  • Steno Diabetes Center Copenhagen, Gentofte, Denmark
Corresponding author
Zobel, Emilie H
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2021-09
Volume
9
Issue
1
Pages
e002395
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3199083247
Cited by
31
References
42
Citations by year
2026: 4 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 4
FWCI
4.10
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Novo Nordisk A/S
  • Skibsreder Per Henriksen, R. og hustrus fund
  • Steno Diabetes Center Copenhagen and Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet have provided internal funding
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords
liraglutide, GLP-1 receptor agonists, type 2 diabetes, plasma lipidome, ceramide, phospholipids, triglycerides, phosphatidylcholine, phosphatidylethanolamine, cardiovascular risk
MeSH terms
Liraglutide, Ceramides, Diabetes Mellitus, Type 2, Humans, Phospholipids, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. https://app.cochat.ai/papers/10.1136/bmjdrc-2021-002395
The paper
Zobel, E. H., Wretlind, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C., & Rossing, P. (2021). Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2021-002395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.